hotspot -WSS

hotspot

author：knowledge 2025-08-12 06:43:48 - browse：8574

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Gain of function research would be limited under House proposal

focus

WSS

Vertex non

5 important ways Henrietta Lacks changed medical science

World's first CRISPR

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

leisure time

hotspot

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Poor hospice wound care hurts patients and families

Dobbs anniversary: the lost opportunity of abortion as health care

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Adults seen as increasingly susceptible to measles

United colonoscopy coverage change 'may cost lives,' doctors say

NYU radiologists take on the challenge of expensive MRI machines

Heart attack and stroke risk calculators need revising

Weight loss drug costs may need more research, senator suggests

focus

EQRx, failed developer of low

New safety details link Apellis eye drug to rare cases of blindness

Surge of respiratory disease in China has likely explanation

Wegovy, Zepbound and weight loss drugs that preserve muscle

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

National panel will explore requiring free Covid tests

leisure time

focus

focus

Wikipedia